Alexion has had a win-some, lose-some year, what with a pricing challenge in the U.K. and a series of recalls for its only marketed drug. But that drug, Soliris, just keeps on surging. Sales grew 39% for the third quarter, hitting $555 million, and profits amounted to $177 million of that.
The Angiomax patent saga has a new chapter. Medicines Co. has now sued its law firms, Ropes & Gray and Fish & Neave, saying lawyers busted deadline for a key patent filing, risking premature generic competition for its best-selling anticoagulant.
Eli Lilly found itself standing at the bottom of a steep slope this year, beleaguered by slumping sales and patent losses for two of its bestselling drugs. The Indianapolis, IN-based company is continuing on its downward spiral, reporting a 16% dip in revenue due to exclusivity losses on anti-depressant Cymbalta and osteoporosis drug Evista.
Celgene's growth engine Revlimid came through again this quarter. The blood cancer drug's $1.3 billion in Q3 sales--a 19% increase--helped the company hit sales estimates and beat profit expectations. And if a new first-line indication wins FDA approval, expected soon, the drug could take another leap next year.
Drugmakers are accustomed to grappling with government payers and PBMs over prices. But a pricing fight directly with patients? That's not your everyday occurrence.
A few potential deals have already caved under the weight of new U.S. tax rules that discourage inversion deals. Not Mylan's. The Pittsburgh-based company is pushing ahead with a $5.3 billion plan to buy a piece of Abbott Laboratories' overseas generics business--with a few edits, of course.
Biogen Idec's new multiple sclerosis pill Tecfidera has been on a roll since its launch last year, with more than $1 billion in sales to its credit already. Today, however, the drug hit a couple of speed bumps: Third-quarter sales missed analyst estimates, and the company announced a patient had died after developing a rare brain infection previously linked to MS drugs.
The saga is familiar: An aging blockbuster loses steam to competing meds, and its maker gets out the cost-cutting ax to compensate.
GlaxoSmithKline said today it is considering a spinoff of ViiV, the successful HIV-centric business it shares with Pfizer and Shionogi. Its talk of unlocking the "intrinsic" value of the business mirrored the language a hedge fund investor used hours earlier to suggest that Amgen do much the same thing, breaking into two companies, one for legacy drugs and one for new launches.
With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline--and, fittingly, for its top management ranks, too.
Following the lead of other Big Pharma heavyweights, Roche is giving its corporate headquarters a facelift. The drugmaker will funnel 3 billion Swiss francs into a renovation project to upgrade its existing facilities and to add new buildings to its Basel, Switzerland-based site.
Despite falling short of its primary endpoint in a trial to examine its effects in cystic fibrosis patients with the R117H mutation, Vertex's Kalydeco has scored an FDA advisory committee recommendation for approval in that population. And the way some see it, that's a sign of much, much bigger approvals to come.
Novartis has the face to launch a Theraflu comeback: entertainer Nick Cannon, who's advising Americans to get ready for flu season by getting vaccinated and stocking up on the over-the-counter remedy.
When Parkinson's disease patients start taking new meds, doctors go on the lookout for the usual side effects: dizziness, nausea, and the like. But according to a new study, they need to think weird, too. The risk of compulsive behavior--gambling, shopping, sex--is much higher than previously thought.
Actavis seems to have a finger in every pie lately when it comes to pharma M&A, and rumor has it Omega Pharma's sales process is no exception.
Valeant's takeover partner, Bill Ackman, is not slowing down in his pursuit to land a deal for Allergan. But a key investor may no longer be quite so gung-ho.
Days after AbbVie recommended that shareholders vote against its proposed $55 billion deal for Shire, the company officially cut the cord and terminated its pending merger. And while Shire has big plans to succeed solo, AbbVie could face a few stumbling blocks without the Dublin-based company by its side.
At least one potential tax-inversion buyout target is pretty happy about the new deal-quashing rules: Actelion CEO Jean-Paul Clozel. In fact, he says, the slap at inversions is not just good for him and Actelion, but for the whole pharma industry.
Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals.
Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.